Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled vs Intravenous Glucocorticoids in Severe AECOPD
NCT06189586Enrolling by invitation
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms). Primary endpoint: Relevant indexes after treatment at Day 10. Started Oct 2021; status: enrolling by invitation.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06189586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189586.